Literature DB >> 32097127

To Treat or Not to Treat: Management Options for Symptomatic Vitreous Floaters.

Geoffrey K Broadhead1,2, Thomas Hong2,3, Andrew A Chang1,2,3.   

Abstract

Vitreous floaters are a common cause for presentation to ophthalmologists, and may significantly affect visual function. In the absence of some more serious underlying pathology such as uveitis, many patients may not experience significant persistent visual impairment from floaters. For some patients, the symptomatic effects of floaters may persist. For these patients, treatment options are available, of which the most commonly reported is vitrectomy. Other treatment modalities have also become more common, notably YAG vitreolysis. Selection of appropriate patients for surgery is often difficult, in part due to the relative lack of objective outcomes with which to measure both visual impairment and improvement post-procedure. Although well-tolerated, vitrectomy does carry with it risks, including iatrogenic retinal breaks, retinal detachment, and in phakic patients, subsequent cataract formation. Techniques such as small gauge vitrectomy, intraoperative examination and treatment of breaks or other worrying lesions, and careful consideration of the need for posterior vitreous detachment induction may help limit the incidence of these adverse events. For other treatment options such as YAG vitreolysis, research and clinical experience remain more limited, and as such the long-term efficacy and risks of these therapies are still unclear. Here, we review the evidence surrounding the role of vitrectomy and YAG vitreolysis in the treatment of vitreous floaters and potential means to minimize therapeutic complications.

Entities:  

Year:  2020        PMID: 32097127     DOI: 10.1097/APO.0000000000000276

Source DB:  PubMed          Journal:  Asia Pac J Ophthalmol (Phila)        ISSN: 2162-0989


  1 in total

1.  The Efficacy and Safety of YAG Laser Vitreolysis for Symptomatic Vitreous Floaters of Complete PVD or Non-PVD.

Authors:  Tiezhu Lin; Tongtong Li; Xinmei Zhang; Yannian Hui; Salissou Moutari; Emmanuel Eric Pazo; Guangzheng Dai; Lijun Shen
Journal:  Ophthalmol Ther       Date:  2021-11-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.